Under the Kigali Amendment to the Montreal Protocol, new controls are being implemented to reduce emissions of HFC-23 (CHF[Formula: see text]), a by-product during the manufacture of HCFC-22 (CHClF[Formula: see text]). Starting in 2015, China and India, who dominate global HCFC-22 production (75% in 2017), set out ambitious programs to reduce HFC-23 emissions. Here, we estimate that these measures should have seen global emissions drop by 87% between 2014 and 2017. Instead, atmospheric observations show that emissions have increased and in 2018 were higher than at any point in history (15.9 [Formula: see text]). Given the magnitude of the discrepancy between expected and observation-inferred emissions, it is likely that the reported reductions have not fully materialized or there may be substantial unreported production of HCFC-22, resulting in unaccounted-for HFC-23 by-product emissions. The difference between reported and observation-inferred estimates suggests that an additional ~309 Tg [Formula: see text]-equivalent emissions were added to the atmosphere between 2015 and 2017.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972758PMC
http://dx.doi.org/10.1038/s41467-019-13899-4DOI Listing

Publication Analysis

Top Keywords

emissions
8
global emissions
8
emissions hfc-23
8
increase global
4
hfc-23
4
hfc-23 despite
4
despite near-total
4
near-total expected
4
expected reductions
4
reductions kigali
4

Similar Publications

Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.

Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.

View Article and Find Full Text PDF

Carbene-metal-amide (CMA) complexes have diverse applications in luminescence, imaging and sensing. In this study, we designed and synthesized a series of CMA complexes, which were subsequently doped into a PMMA host. These materials demonstrate light-induced dynamic phosphorescence, attributed to their long intrinsic triplet state lifetime (τP,int, in the μs-ms scale), high intersystem crossing (ISC) rate constant (kISC, up to 107 s-1), and bright phosphorescence.

View Article and Find Full Text PDF

In this study, nitrogen-doped carbon nanodots (N-CDs) with temperature and fluorescence sensing were prepared via hydrothermal method using L-lysine and ethylenediamine as precursors. The synthesized N-CDs exhibited spherical morphology with sizes ranging from 2.8 to 5.

View Article and Find Full Text PDF

This study addresses the critical issue of irreversible oxidation in hypochlorite (ClO⁻) sensing by a phenothiazine-based compound, which typically leads to the probe's degradation and loss of functionality. We introduce a novel fluorescence probe, (2-(5-(10 H-phenothiazin-10-yl)thiophen-2-yl)-1 H-benzo[d]imidazol-6-yl)(phenyl)methanone (PTH-BP), specifically designed to enhance ClO⁻ detection efficiency. PTH-BP exhibits strong aggregation-induced emission (AIE), emitting deep orange fluorescence at 620 nm with a large Stokes shift of 195 nm, and achieves an impressive detection limit of 1 nM in ACN/PBS buffer solutions.

View Article and Find Full Text PDF

Preclinical evaluation of the potential PARP-imaging probe [carbonyl-C]DPQ.

EJNMMI Radiopharm Chem

January 2025

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.

Background: Poly (ADP-ribose) polymerase (PARP) enzymes are crucial for the repair of DNA single-strand breaks and have become key therapeutic targets in homologous recombination-deficient cancers, including prostate cancer. To enable non-invasive monitoring of PARP-1 expression, several PARP-1-targeting positron emission tomography (PET) tracers have been developed. Here, we aimed to preclinically investigate [carbonyl-C]DPQ as an alternative PARP-1 PET tracer as it features a strongly distinct chemotype compared to the frontrunners [F]FluorThanatrace and [F]PARPi.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!